BLAINJECTIONINJECTABLE
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
VYEPTI (eptinezumab-jjmr) by Lundbeck is calcitonin gene-related peptide antagonists [moa]. First approved in 2020.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VYEPTI (eptinezumab-jjmr) is a monoclonal antibody antagonist of calcitonin gene-related peptide (CGRP), a neuropeptide implicated in migraine pathogenesis. Administered as an intravenous injection, it is indicated for migraine prevention in adults. The drug works by blocking CGRP signaling, reducing the frequency and severity of migraine episodes.
$0.009BPart D
PeakVYEPTI is in peak commercial phase with modest Part D utilization (2,486 claims in 2023), indicating a niche market position within the competitive CGRP antagonist class.
Mechanism of Action
Calcitonin Gene-related Peptide Antagonists
Pharmacologic Class:
Calcitonin Gene-related Peptide Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VYEPTI offers exposure to the high-value migraine prevention market and differentiated IV dosing strategy, though limited linked job postings (0) indicate modest hiring velocity. The peak lifecycle stage means roles focus on market penetration, payer management, and defending market share against CGRP competitors rather than launch execution.
Brand Manager
Worked on VYEPTI at Lundbeck? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.